Title: Comparison of different second line treatments for metastatic pancreatic cancer: a
systematic review and network meta-analysis
Version: 2 Date: 19 Mar 2023
Reviewer:  Qiancheng Hu
Reviewer's report:
Recently, the pairwise meta-analysis showed  fluoropyrimidine combination therapy had a
higher response rate and longer PFS in patients with gemcitabine-refractory advanced pancreatic
cancer compared with fluoropyrimidine monotherapy. Your topic is very good. However, I don't
think this article is fit for publication.  There are a lot of questions in this article.  Firstly, based
on your eligibility criteria in the NMA, MPACA-3 (Eur J Cancer. 2021 Nov;157:21-30) might
be included. Second, abbreviations (eg, PF, OXA,PEG) are best explained clearly in the picture.
Lastly, quality evaluation is also an important part of NMA.
Title: Comparison of different second line treatments for metastatic pancreatic cancer: a
systematic review and network meta-analysis
Version: 2 Date: 19 Mar 2023
Reviewer:  Qiancheng Hu
Reviewer's report:
Recently, the pairwise meta-analysis showed  fluoropyrimidine combination therapy had a
higher response rate and longer PFS in patients with gemcitabine-refractory advanced pancreatic
cancer compared with fluoropyrimidine monotherapy. Your topic is very good. However, I don't
think this article is fit for publication.  There are a lot of questions in this article.  Firstly, based
on your eligibility criteria in the NMA, MPACA-3 (Eur J Cancer. 2021 Nov;157:21-30) might
be included. Second, abbreviations (eg, PF, OXA,PEG) are best explained clearly in the picture.
Lastly, quality evaluation is also an important part of NMA.
Please review this paper.
user
Title: Comparison of different second line treatments for metastatic pancreatic cancer: a
systematic review and network meta-analysis
Version: 2 Date: 19 Mar 2023
Reviewer:  Qiancheng Hu
Reviewer's report:
Recently, the pairwise meta-analysis showed  fluoropyrimidine combination therapy had a
higher response rate and longer PFS in patients with gemcitabine-refractory advanced pancreatic
cancer compared with fluoropyrimidine monotherapy. Your topic is very good. However, I don't
think this article is fit for publication.  There are a lot of questions in this article.  Firstly, based
on your eligibility criteria in the NMA, MPACA-3 (Eur J Cancer. 2021 Nov;157:21-30) might
be included. Second, abbreviations (eg, PF, OXA,PEG) are best explained clearly in the picture.
Lastly, quality evaluation is also an important part of NMA.
assistant